In the identical calendar year the ITC also reported on their initiatives towards the circulation syntheses of two guide compounds noted previously by AstraZeneca. The primary just one information the movement synthesis of a powerful 5HT1B antagonist (28) that was assembled via a five stage ongoing synthesis including a SNAr response, heterogeneous